Domagalska Dorota, Grzechulski Bartosz, Paszkowski Jacek, Gałęcka Mirosława, Banasiewicz Tomasz
Department of General, Endocrine Surgery and Gastroenterological Oncology, Poznan University of Medical Science, Poznan, Poland.
Institute of Microecology, Poznan, Poland.
Prz Gastroenterol. 2020;15(3):253-257. doi: 10.5114/pg.2020.99040. Epub 2020 Sep 19.
Post-operative impairment of gastrointestinal tract function and metabolic consequences occur in patients after gastrectomy by Roux-en-Y method. Short-chain fatty acids and silicon dioxide may prove beneficial in the treatment of these conditions.
To evaluate a preparation containing propionic acid and silicon dioxide on the body weight, number of stools and their consistency (the Bristol scale), and pain and a feeling of gastric fullness after a meal, in patients after gastrectomy by Roux-en-Y method.
Measurements were performed at the beginning of the study, on day 7 and 14 of application (Colostop; Miralex, 2 × 15 g/day).
Initially the average daily number of movements was 10/day, after the therapy it was 3.8/day. At the beginning of the study, 3 patients described their faeces as type 6 and two as type 7 on the Bristol scale. After supplementation, 3 patients described stool consistency as type 5, and two as type 4. Initially, patients rated their pain at 3.4/10 on average, the stomach fullness as 4.6/10. At the end of the study, 3 patients did not feel any pain, while others reported pain at 1/10. Four patients described their feeling of gastric fullness as 1/10, and 1 no longer observed this feeling. Patients disclaimed any adverse effects, and satisfaction after therapy reached 9-10/10 points. Patients' body weight did not change significantly. An improvement in standard diet tolerance was observed. Despite the limited study group, clinical benefits of the supplementation were observed.
采用Roux-en-Y法行胃切除术后的患者会出现胃肠道功能术后损伤及代谢后果。短链脂肪酸和二氧化硅可能对治疗这些情况有益。
评估一种含有丙酸和二氧化硅的制剂对采用Roux-en-Y法行胃切除术后患者的体重、排便次数及其稠度（布里斯托量表）、餐后疼痛和饱腹感的影响。
在研究开始时、用药第7天和第14天（Colostop；Miralex，2×15 g/天）进行测量。
最初平均每日排便次数为10次/天，治疗后为3.8次/天。研究开始时，3名患者将其粪便在布里斯托量表上描述为6型，两名患者描述为7型。补充后，3名患者将粪便稠度描述为5型，两名患者描述为4型。最初，患者平均将疼痛评分为3.4/10，饱腹感评分为4.6/10。研究结束时，3名患者没有感到任何疼痛，而其他患者报告疼痛为1/10。4名患者将其饱腹感描述为1/10，1名患者不再有这种感觉。患者否认有任何不良反应，治疗后的满意度达到9 - 10/10分。患者体重没有显著变化。观察到标准饮食耐受性有所改善。尽管研究组有限，但观察到了补充剂的临床益处。
